Forbion raises $2.6B for biotech in a capital-starved market
What's the deal? ForbionDealroom has a profile for this one. Try Dealroom →, Europe's largest dedicated life sciences venture capital firm, has raised €2.3 billion ($2.6 billion) across two new funds — its largest fundraising to date. The raise splits across ForbionDealroom has a profile for this one. Try Dealroom → Growth Opportunities Fund IV and Forbion Ventures Fund VIII, and brings the firm's assets under management to roughly €7.5 billion.
Where's the money going? The two funds together can finance about 30 portfolio companies, with first investments already completed. Fund IV targets later-stage biopharma firms in Europe and North America; Fund VIII backs therapeutics-focused biotech companies.
Who backed it? Investors include MN, PGGM, KfW Capital, the Kauffman FoundationDealroom has a profile for this one. Try Dealroom →, and Eli Lilly and CompanyDealroom has a profile for this one. Try Dealroom →, with support from both existing and new backers. The fundraising substantially exceeded its target.
Why now? Forbion is deploying capital into a sector short on it. "Our successful fundraising gives us significant dry powder in a market characterized by a general shortage of capital," said Sander Slootweg, managing partner and co-founder.
The track record: Over 20 years, Forbion has financed 142 companies, including 37 it created itself. Its portfolio has delivered 21 approved medical products benefitting more than 1.6 million patients globally.
The signal: One of the largest life sciences venture raises worldwide in five years, Forbion's haul shows large investors still back specialist managers with proven returns — even as broader biotech funding tightens.
Read more: pr.holladayjournal.com
Image credit: Generated with Gemini
